行情

NAVB

NAVB

Navidea生物制药
AMEX
0.2468
+0.0012
+0.49%
交易中 13:01 09/29 EDT
开盘
0.2457
昨收
0.2456
最高
0.2510
最低
0.2457
成交量
5,646
成交额
765
52周最高
1,530.50
52周最低
0.2250
市值
749.46万
市盈率(TTM)
-0.6170
分时
5日
1月
3月
1年
5年
Navidea Biopharmaceuticals 在类风湿性关节炎的 3 期试验中开设新地点;与 Jubilant 终止谅解备忘录
Navidea Biopharmaceuticals 在类风湿性关节炎的 3 期试验中开设新地点;与 Jubilant 终止谅解备忘录
MT Newswires · 09/01 10:54
NAVB 简况
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. Its business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. The Company has developed processes for producing the first two therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which targets activated CD206+ macrophages, and the Manocept dexamethasone (MAN-DEX) series, which inhibits the inflammatory activity of activated CD206+ macrophages.

微牛提供Navidea Biopharmaceuticals Inc(AMEX-NAVB)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NAVB股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NAVB股票基本功能。